Stocks in Focus for February 17: BHEL, Smvardhana Motherson, RVNL, Glenmark Pharma & Others

BHEL State-run engineering firm BHEL has announced a major contract win, landing BHEL share price of Rs6,700 million from Singareni Collieries Company (SCCL) to set up an 800MW thermal power plant located in Telangana. The contract, which was awarded according to basis of an Engineering, Procurement, and Construction (EPC) basis includes design manufacturing, engineering supplies, erection commissioning, as well as civil works associated with the project.

Samvardhana Motherson: However, it was less than estimates of Samvardhana Motherson share price Rs29371 crore. EBITDA was up 13% year-on-year at Rs2,687.4 crore, which is similar to estimates of Rs2,698 crore as margins increased to 9.7%, up from 9.2 percent in the previous year which was higher than expectations of 9.2 percent.

RVNL RSS feed State-owned company has reported an 13.1 percent year-on year (YoY) decline in its net profits of Rs311.6 crore in the third quarter which was completed on December 31st 2024. In the same time frame in FY24, the company posted net profits in the range of Rs358.6 crore. RVNL share price dropped 2.6 percent to Rs4,567.4 crore compared to Rs4,689.3 crore during the prior year period. On the operational scale, EBITDA (earnings before interest tax, depreciation and taxes and amortization) decreased by 3.9 percentage year-over-year, up to Rs239.4 million in the quarter ended March 31, 2015 compared to the previous quarter of Rs249 crore.

Glenmark Pharma: Glenmark Pharma reported net revenues for Q3FY25 of Glenmark Pharma share price Rs347.9 crore after covering deficit liabilities totaling Rs351.3 crore, revenue increased 35.1 percent year on year to reach 3,387.6 crore versus Rs2,506.7 in Q3 of last fiscal. Revenue increased 35 percent year-over-year; EBITDA saw significant improvement by reaching Rs600.3 crore as it surged against an operating loss in previous year quarter of Rs208.7 Million.